Article

Quantel Medical debuts IPL system for dry eye treatment

According to the company, its C.STIM IPL system is based on intense pulsed light technology for the treatment of dry eye disease.

Quantel Medical's C.STIM IPL system, based on intense pulsed light technology for the treatment of dry eye disease.

Quantel Medical's C.STIM IPL system, based on intense pulsed light technology for the treatment of dry eye disease.

Quantel Medical today announced the launch of its C.STIM IPL system, based on intense pulsed light technology for the treatment of dry eye disease.

Dry eye is a huge public health problem affecting more than 700 million people in the word and it is the most common pathology in ophthalmic visits. Dry eye treatment is now a key question in many specialties like glaucoma, refractive & cataract surgeries, contact lenses and others.

The company pointed out in a news release that the IPL system treats the root causes of dry eyes: Meibomian gland dysfunction, inflammation, and Demodex, to stop the vicious cycle of dry eye.

According to Delphine Southon, dry eye product manager, C.STIM, the platform offers clinical efficacy and patient comfort.

C.STIM has been designed with the aim of combining cutting-edge technology with a sleek, robust and ergonomic design. The device integrates the best technological features to guarantee efficacy, safety, ergonomics and to offer a “plug and play” product easy delegable.

“Drawing on Quantel Medical’s years of experience in intense pulsed light in dermatology, we have now developed an IPL device exclusively for use in ophthalmology designed and manufactured by the Lumibird Medical Group, said said Jean-Marc Gendre, CEO of Lumibird Medical.

Gendre said the product will offer a therapeutic solution to ophthalmologists to treat patients with dry eye disease.

According to the news release, Quantel Medical provides ophthalmologists with therapeutic laser solutions to treat the four main causes of blindness: glaucoma, cataracts, diabetic retinopathy and macular degeneration.

Lumibird Medical is the medical holding of the Lumibird Group, a company invoolvled in the development of solid-state lasers for scientific and industrial use. It comprises Quantel Medical (France and Polska) and Ellex (Australia, Japan and United States), since July 2020, along with Optotek Medical in Slovenia and Lumibird Medical Nordics (Sweden, Finland and Norway)

Related Videos
AAO 2024: Matt Giegengack, MD: Injectable endothelial cell therapy shows promise for improving vision and reducing glare in corneal edema
EyeCon 2024: Adam Wenick, MD, talks about myopic interventions across the lifespan
Adam Wenick, MD, chairs EyeCon session: New treatments in geographic atrophy from detection to intervention
EyeCon 2024: Laura M. Periman, MD, shares her passion for dry eye disease, discussing her surprising discovery of the Alpenglow Sign in Demodex blepharitis
David Eichenbaum, MD, presents advances in AMD therapy, highlights different mechanisms with a common goal
Fasika Woreta, MD, MPH, Eugene de Juan, M.D. Professor of Ophthalmic Education at Wilmer Eye Institute’s Baltimore and Columbia locations, discusses the NMA meeting
Cochair Kelly K. Nichols, OD, PhD, MPH, FAAO, highlights her passion for dry eye research and the vital collaboration between ophthalmology and optometry
Alice Epitropoulos, MD, and Laura M. Periman, MD
© 2024 MJH Life Sciences

All rights reserved.